<SEC-DOCUMENT>0001140361-24-018449.txt : 20240408
<SEC-HEADER>0001140361-24-018449.hdr.sgml : 20240408
<ACCEPTANCE-DATETIME>20240408060400
ACCESSION NUMBER:		0001140361-24-018449
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240407
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240408
DATE AS OF CHANGE:		20240408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		24828010

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20026226_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ions="http://ionispharma.com/20240407" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_4c57c4ed6ff34add94f196511c84671f" contextRef="c20240407to20240407" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_69adc1967ef64840aeb19b2496cc1026" contextRef="c20240407to20240407">0000874015</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_ceb4d859cb5744d282405d1805b4255f" contextRef="c20240407to20240407">CA</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_8153900da25e492695ec7b775b033e7a" contextRef="c20240407to20240407">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20240407.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240407to20240407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-07</xbrli:startDate><xbrli:endDate>2024-04-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">
  </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_0359e6de82be44dd8b5db4467b24326c" contextRef="c20240407to20240407">8-K</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;SECURITIES EXCHANGE ACT OF 1934</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_f1288a21b56d41c0900e7ca5fb1200d9" contextRef="c20240407to20240407" format="ixt:date-monthname-day-year-en">April 7, 2024</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_fbd1443b9c8d43da8c555b1bc471535b" contextRef="c20240407to20240407">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_e57ff38bc47f491084d0659e93ecb7d6" contextRef="c20240407to20240407" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_6eb1ae5114bb4de08ae5c3f6e09bcbee" contextRef="c20240407to20240407">000-19125</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_0da8264635ef4d8da06c142aee979f56" contextRef="c20240407to20240407">33-0336973</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">(Commission File No.)</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_40ad2f93d6fe4b75b2d3607d04195b05" contextRef="c20240407to20240407">2855 Gazelle Court</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_59516e5b03ba4320b9d28b9534ddf9ba" contextRef="c20240407to20240407">Carlsbad</ix:nonNumeric>, <span style="-sec-ix-hidden:Fact_ceb4d859cb5744d282405d1805b4255f">CA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_b67a1d74d06949c59723fe2a82eccd9d" contextRef="c20240407to20240407">92010</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_11955e53681d4d68bec9832dab95a509" contextRef="c20240407to20240407">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_9996822d01e54e9d9b8745dc4651be5c" contextRef="c20240407to20240407">931-9200</ix:nonNumeric></span></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;"> <br/>
          </span></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
<div><span style="font-weight: bold;"> </span></div>
</div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_a840f08092274add96f0ee9fb869a031" contextRef="c20240407to20240407" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_eda278a0d00c40568d38faad5b4a7f30" contextRef="c20240407to20240407" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_15d5501369fa4e46885a9a473f60bfc3" contextRef="c20240407to20240407" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_0d1afa95d59f4cc28c5aea0dde5860d0" contextRef="c20240407to20240407" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
            </td>

    <td style="width: 4.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Trading symbol</div>
            </td>

    <td style="width: 4.57%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8519f9bc17f3430d80285ed280906074" contextRef="c20240407to20240407">Common Stock, $.001 Par Value</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 4.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_60367cb75a0f48b9b94187523a89d59d" contextRef="c20240407to20240407">&#8220;IONS&#8221;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 4.57%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_8153900da25e492695ec7b775b033e7a">The Nasdaq Stock Market, LLC</span><br/>
              </div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
        Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

      <div style="text-align: right; text-indent: 288pt; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_119de963ad254a7b97d3969bedc8e90c" contextRef="c20240407to20240407" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
        revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="color: rgb(0, 0, 0);"> &#9744;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On April 7, 2024, Ionis Pharmaceuticals, Inc. issued a press release announcing positive results from the Phase 3 Balance study of olezarsen for the
        treatment of adults with familial chylomicronemia syndrome (FCS).</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 16%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
            </td>

    <td style="width: 84%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20026226_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 84%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Press Release dated April 7, 2024.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 84%; vertical-align: top;" rowspan="1"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 16%; vertical-align: top; text-align: center;" rowspan="1">104</td>

    <td style="width: 84%; vertical-align: top;" rowspan="1">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
        on its behalf by the undersigned, thereunto duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify;">Dated:&#160; April 8, 2024</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify;">By: <br/>
              </div>
            </td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Patrick R. O&#8217;Neil</td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 3%;">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold;"><br/>
              </div>
            </td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; width: 47%;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 3%;"><br/>
            </td>

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 47%;">
              <div style="text-align: justify; font-family: 'Times New Roman';">Executive Vice President, Chief Legal Officer and General Counsel</div>
            </td>

  </tr>


</table>
      <div><br/></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;">
  </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20026226_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 99.1</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome</div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zddd743215b7b46cd9c118d9629b3d517" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute
                pancreatitis events &#8211;</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7b124ff24dd04b0c848b32711fa678e8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S. &#8211;</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5d58727cf0cf496e901f4466ac2d9621" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">Data presented today at ACC 2024 and published in The New England Journal of Medicine &#8211;</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf2a8e7b21afe47de88b32c0cb6c71996" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8211;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">Ionis to host webcast on Monday, April 8 at 10:00 am ET &#8211;</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CARLSBAD, Calif., April 7, 2024 --</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman';"><u>Ionis Pharmaceuticals, Inc.</u> </font>(Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis&#8217; lead independent investigational medicine, olezarsen, for the treatment of
          adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen
          demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels. Importantly, olezarsen reduced the incidence of acute pancreatitis (AP) events over the 12-month treatment period compared to placebo. Olezarsen
          also demonstrated a favorable safety and tolerability profile. These results were presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia and published simultaneously in The <font style="font-family: 'Times New Roman'; font-style: italic;">New England Journal of Medicine (NEJM).</font> Based on these data, Ionis is pursuing regulatory approval of olezarsen as a potential breakthrough treatment for adults with FCS.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;As a physician who has seen first-hand the struggles of people living with FCS and its serious complications, there is significant need for an effective
        therapy to lower triglycerides and reduce acute pancreatitis events,&#8221; said Erik Stroes, MD, professor of medicine, Amsterdam University Medical Centers, and a principal investigator of the Balance study. &#8220;Olezarsen represents a potentially
        life-changing new medicine for these patients who experience debilitating chronic symptoms, including abdominal pain and cognitive symptoms, as well as hospitalizations associated with potentially fatal acute pancreatitis events.&#8221;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance Study Results</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In the study, patients were treated with olezarsen 80 mg (n=22), 50 mg (n=21) or placebo (n=23) once every four weeks.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z27f2a1d7066b4e3ca97fdb643edc464c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In the 80 mg group, olezarsen met the primary endpoint, with a statistically significant placebo-adjusted reduction in TG levels from baseline to six months (44%, p&lt;0.001).</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z3a99af4d748444058e063014dfb8b556" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Reductions from six to 12 months were sustained, with olezarsen 80 mg achieving a placebo-adjusted 59% reduction in TGs.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf1d3ecae0bb04c6a945ce3a0855705ca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">ApoC-III placebo-adjusted reductions were robust and sustained at six and 12 months (74% and 81% reductions, respectively).</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z589be4bc8a514f55bc163d8d99216147" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In the 50 mg group, olezarsen reduced TG levels, however this difference was not statistically significant at six months compared to placebo (22%, p=0.078).</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zae8bb45cf61a4be68a4caa171ca6dfef" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Reductions from six to 12 months were improved, with olezarsen 50 mg achieving a placebo-adjusted 44% reduction in TGs.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zfaf0a2d3be20491ea930c1b8dc3c0220" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Olezarsen-treated patients had markedly fewer AP events during the 12-month period, compared to placebo.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z614b60a3ed5049f7834bc8db91f7762a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Eleven episodes of AP occurred in the placebo group versus one episode in the 80 mg olezarsen group and one episode in the 50 mg group.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z255150efd7974d6abffc96e9faf93ea4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Furthermore, there was a substantially greater time to the first event with olezarsen compared to placebo (one year (80 mg) and 102 days (50 mg), vs. nine days for placebo).</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="za6920c33141a478795c64ce1ae9aaa27" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Olezarsen-treated patients experienced a placebo-adjusted 84% reduction in all-cause hospitalizations between baseline and 12 months.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb11ff8b0f91248129394a9ab95ff20b5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">A favorable safety and tolerability profile was observed, with a higher number of treatment-emergent adverse events (TEAEs) in the placebo group. There were no serious TEAEs related to olezarsen.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zff8bfd33d1b14782a9239117737f3517" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">The most common AEs were COVID-19, abdominal pain and diarrhea, none of which were more frequent in patients treated with either dose of olezarsen versus placebo.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z69ba13b6b44a409cbe030598621ea708" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">o</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Serious AEs occurred in 14% of patients treated with olezarsen 80 mg, 19% treated with olezarsen 50 mg, and 39% treated with placebo.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Balance is the first clinical study to validate the association of reduced triglyceride levels with reduced incidence of acute pancreatitis events in patients with
        severely elevated triglycerides. This important finding supports the potential for olezarsen to be the standard of care for patients with FCS, if approved. These data further strengthen our confidence for a successful outcome in the ongoing Phase 3
        CORE studies evaluating olezarsen in the much more prevalent severe hypertriglyceridemia patient population,&#8221; said Brett P. Monia, Ph.D., chief executive officer of Ionis. &#8220;Our team looks forward to working closely with the FDA to advance the first
        potential treatment for FCS in the U.S., and to successfully delivering Ionis&#8217; first independent commercial launch later this year, assuming priority review. We offer our sincerest gratitude to the patients and investigators who participated in
        this pivotal study.&#8221;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The ACC Balance presentation can be found on <u><font style="font-family: 'Times New Roman';">Ionis&#8217; website</font></u> after today&#8217;s presentation at
        10:08 am ET.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In addition to the Balance data, a late-breaking abstract entitled, &#8220;Efficacy and Safety of Olezarsen in Patients with Hypertriglyceridemia and High
        Cardiovascular Risk: Primary Results of the Bridge-TIMI 73a Trial&#8221; was also presented at ACC and published in <font style="font-family: 'Times New Roman'; font-style: italic;">NEJM</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Webcast</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Ionis will host a webcast to discuss the detailed results from the Balance study on Monday, April 8 at 10:00 am ET. Interested parties may access the
        webcast <u><font style="font-family: 'Times New Roman';">here</font></u>. A webcast replay will be available for a limited time.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the Balance Study</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The global, multicenter, randomized, double-blind, placebo-controlled Phase 3 Balance study (<u><font style="font-family: 'Times New Roman';">NCT04568434</font></u>)
        enrolled 66 patients aged 18 and older with confirmed FCS. Patients in the study received background therapies including statins, fibrates and omega-3 fatty acids. Patients were randomized in a 1:1:1 ratio to receive olezarsen 80 mg or 50 mg or
        placebo via subcutaneous injection once every four weeks for 53 weeks. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in
        triglyceride levels at 12 months, percent changes in other lipid parameters, and adjudicated acute pancreatitis event rates over the treatment period.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Olezarsen</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen is an RNA-targeted investigational <font style="font-family: 'Times New Roman'; font-weight: bold;">LI</font>gand <font style="font-family: 'Times New Roman'; font-weight: bold;">C</font>onjugated <font style="font-family: 'Times New Roman'; font-weight: bold;">A</font>ntisense (LICA) medicine being evaluated for people at risk of disease due to elevated triglyceride levels,
        including those with familial chylomicronemia syndrome (FCS). Olezarsen is designed to inhibit the body&#8217;s production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1,2</sup> The U.S. FDA
        granted <u><font style="font-family: 'Times New Roman';">olezarsen Fast Track designation</font></u> for the treatment of FCS in January 2023, as well as <u><font style="font-family: 'Times New Roman';">Orphan Drug designation</font></u><font style="font-family: 'Times New Roman';">&#160;</font>and<font style="font-family: 'Times New Roman';">&#160;</font><u><font style="font-family: 'Times New Roman';">Breakthrough Therapy designation</font></u><font style="font-family: 'Times New Roman';"> i</font>n
        February 2024. In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in Phase 3 clinical trials.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen is an investigational medicine that has not been reviewed or approved for the treatment of any disease by any regulatory authority.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About FCS</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">FCS is a rare, genetic </font><font style="font-size: 10pt;">disease characterized by
          extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL).<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein
          particles that are 90% triglycerides.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3,4</sup> FCS is estimated to impact one to 13 people per million in the U.S.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5,6,7</sup> People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues
          such as fatigue and severe, recurrent abdominal pain.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3,8,9</sup> People living with FCS are sometimes unable to work, adding to the burden of disease.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">9</sup></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Currently, there are no U.S. FDA-approved therapies for the treatment of FCS and standard triglyceride lowering therapies are generally ineffective in patients with FCS.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">10,11</sup>
        People living with this condition currently rely solely on nutrition management through extremely restrictive and difficult to manage diets <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">to navigate the health risks associated
          with FCS.</font><sup style="color: #000000; vertical-align: text-top; line-height: 1; font-size: smaller;">11,12</sup></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and
        a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep
        understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit <u><font style="font-family: 'Times New Roman';">Ionispharma.com</font></u>
        and follow us on X (Twitter) and LinkedIn.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-looking Statements</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release includes forward-looking statements regarding olezarsen, Ionis&#8217; business, and the therapeutic and commercial potential of Ionis&#8217; commercial medicines,
        additional medicines in development and technologies. Any statement describing Ionis&#8217; goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Such
        statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and
        commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis&#8217; forward-looking statements also involve assumptions that, if they never materialize or
        prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis&#8217; forward-looking statements reflect the good faith judgment <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result,
          you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis&#8217; programs are described in additional detail in Ionis&#8217; annual report on Form 10-K for the year ended Dec. 31, 2023, and most recent Form
          10-Q, which are on file with the SEC. Copies of these and other documents are available at </font><u><font style="font-family: 'Times New Roman';">www.ionispharma.com</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of Ionis Pharmaceuticals, Inc.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Media Contact:</font><font style="font-size: 10pt;"> Hayley Soffer, 760-603-4679; <font style="font-family: 'Times New Roman'; font-weight: bold;">IR Contact</font>: Wade Walke, 760-603-2331</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">###</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>Alexander VJ, et al. Eur Heart J 2019;40(33):2785-2796.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>Tardif JC, et al. Eur Heart J 2022;43(14):1401-1412.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup>Gaudet D, et al. N Engl J Med. 2014;371:2200-2206.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup>Ginsberg HN, et al. Eur Heart J. 2021;42:4791-4806.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup>Pallazola VA, et al. Eur J Prev Cardiol 2020;27(19):2276-8.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6</sup>Warden BA, et al. J Clin Lipidol 2020;14(2):201-6.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7</sup>Tripathi M, et al. Endocr Pract 2021;27(1):71-6.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">8</sup>Bashir B, et al. Metabolites. 2023;(5):621.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">9</sup>Davidson M, et al. J Clin Lipidol. 2018;12(4):898-907.e2.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">10</sup>Gouni-Berthold I. J Endocr Soc. 2019;4(2):bvz035.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">11</sup>Paquette M, et al. Atherosclerosis. 2019;283:137-142.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">12</sup>Williams L, et al. J Clin Lipidol. 2018;4:908-919.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20240407.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<xs:schema targetNamespace="http://ionispharma.com/20240407" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionispharma.com/20240407" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20240407_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20240407_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20240407_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20240407_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.3.1.5224 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionispharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20240407.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionispharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140580802614240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  07,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">&#8220;IONS&#8221;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !],(A8'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ ?3"(6"0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( 'TPB%AED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !],(A86J1$3.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !],(A8
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( 'TPB%@=AELY8 0  * 0   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !],(A8
MGZ ;\+$"  #B#   #0              @ &D#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( 'TPB%B7BKL<P    !,"   +              "  8 /  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'TPB%@<.&7J/P$  #P"   /
M      "  6D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !],(A8)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !],(A899!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20026226_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:SecurityExchangeName -  ef20026226_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20026226_8k.htm">ef20026226_8k.htm</File>
    <File>ions-20240407.xsd</File>
    <File>ions-20240407_lab.xml</File>
    <File>ions-20240407_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20026226_8k.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionispharma.com/20240407",
   "dts": {
    "inline": {
     "local": [
      "ef20026226_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20240407.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20240407_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20240407_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://ionispharma.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240407to20240407",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20026226_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240407to20240407",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20026226_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ionispharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-24-018449-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-018449-xbrl.zip
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MYQ.?L69Y#47S-'TUK5$1AOF\.I7(IGR4T4;DUG='[9*#&X[\NA;Z&D][1=*
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MW [IC9V:>B376"G<DS-[=F=FAPNTE?>S^Z%K"[<>C1^%9*B0^VJ]6G,7>N&
MB-,(:7F(8>X-N^4!@=L[^<:/-LV/,-S.:W%V5HG3L/:P==Q).^#29CPDWU"_
MC2Z+,QPN6!AM[:.^F9;78UK00KZ>V[+L3%J>*S&-*F*X)3$>0J QL3;*Y.LQ
MP2_(R-M\0[13+)Z%A406M3Q*Z)\A84CDG^0)_/NH.PQ9@,[9#8Z*8X:XW(WX
MS&+&X9DXC31E6_'//:F(G-#?Z2N;G5?3_ "'Q52G6/G; <_\UPD..^+ON<B_
M[Y*-HN/_ %!+ P04    " !],(A8AK;Z4#L:  #B@P  %0   &5F,C P,C8R
M,C9?97@Y.2TQ+FAT;>U=:W/;1K+]OE7['V:=RJY41=( "+XD.U6R;"?V]4/7
MTF[NUP$P("<& 2X>DNE??T_W#!ZD*-NR%5NJR$G9% @,IF?Z<;JGN_5H42Z3
M7_[^-R$>+92,^!,^E[I,U"^/'II_[<5_]/OBE0Y56JA(E-F!>))G,LIU-%?F
M#O[S- NKI4I+$>9*EKBS*G0Z[]PK3MZ]C76BA.</A@-W,/(\O_/\<;9:YWJ^
M*(4[FXU$7WB.YW<?[_?-?!_:"3\*LF@M@GF8)5G^^,%/,?]Y((IRG:C'#^(L
M+?NQ7.ID?2#^=::7JA!OU(5XERUE^J]#P=\7^J,Z$*ZS*@]%J3Z4?9GH>7H@
M$A7C"H]\('YR^,_A _-^>G#C)9U!'OR"^=%%<VNDS^M%7.0BS8J%C/"4_?!
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M\^DS3IGUA?[^MT</*>N8/RS*98(/_P]02P,$%     @ ?3"(6%2BVC5& P
M0@\  !$   !I;VYS+3(P,C0P-# W+GAS9+576V_3,!1^1^(_F+P[EZ8#6JV;
M0-O0I,'0 (DWY#I.:^'8P799^^^QG3A-KS0-O#D^Y[O8/L=U+Z^7!0._B514
M\$F0A'$ ",<BHWPV"18*(H4I#:ZO7KZX? 7A!\*)1)ID8+H"[Z5 F:39C(#/
M3X\Y900,AF$:)N'%8#!LA2&T\*4:*SPG!0(:R1G1GU!!5(DPF01SK<MQ%!D+
M5)5S) L48E%$@W@PC(?Q&V.)D8)P?2=D<4-RM&!Z$OQ:($9S2K( F#5P-5ZJ
MANGY^3E\3D,A9X8D3J+O'Q^^.&V?:Z34";I5,J/\YP;U<BJ9)T\C&YXB11H?
M._FUE60T&D4NVJ0:(GJ$FG*E$<>DG9_I!M!.OHBJH$_-"-W,4P2',_$[,@&[
MPK1)U!+J54G4?A\F'-FPQ0Q@G,(T\4A3'IO '*FI _G(AI"2^E!^$ZH IEP
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MG7>5ZA4:JO5N#B[8)_[6UKHIJ=YR.OL?4$L#!!0    ( 'TPB%C!QT1RWP4
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M     &5F,C P,C8R,C9?.&LN:'1M4$L! A0#%     @ ?3"(6(:V^E [&@
MXH,  !4              ( !R!$  &5F,C P,C8R,C9?97@Y.2TQ+FAT;5!+
M 0(4 Q0    ( 'TPB%A4HMHU1@,  $(/   1              "  38L  !I
M;VYS+3(P,C0P-# W+GAS9%!+ 0(4 Q0    ( 'TPB%@'\.6*>@@  #!6   5
M              "  :LO  !I;VYS+3(P,C0P-# W7VQA8BYX;6Q02P$"% ,4
M    " !],(A8P<=$<M\%  #W/@  %0              @ %8.   :6]N<RTR
E,#(T,#0P-U]P<F4N>&UL4$L%!@     %  4 1P$  &H^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ef20026226_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20240407.xsd" xlink:type="simple"/>
    <context id="c20240407to20240407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2024-04-07</startDate>
            <endDate>2024-04-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240407to20240407"
      id="Fact_4c57c4ed6ff34add94f196511c84671f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240407to20240407"
      id="Fact_69adc1967ef64840aeb19b2496cc1026">0000874015</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240407to20240407"
      id="Fact_ceb4d859cb5744d282405d1805b4255f">CA</dei:EntityAddressStateOrProvince>
    <dei:SecurityExchangeName
      contextRef="c20240407to20240407"
      id="Fact_8153900da25e492695ec7b775b033e7a">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20240407to20240407"
      id="Fact_0359e6de82be44dd8b5db4467b24326c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240407to20240407"
      id="Fact_f1288a21b56d41c0900e7ca5fb1200d9">2024-04-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240407to20240407"
      id="Fact_fbd1443b9c8d43da8c555b1bc471535b">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240407to20240407"
      id="Fact_e57ff38bc47f491084d0659e93ecb7d6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240407to20240407"
      id="Fact_6eb1ae5114bb4de08ae5c3f6e09bcbee">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240407to20240407"
      id="Fact_0da8264635ef4d8da06c142aee979f56">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240407to20240407"
      id="Fact_40ad2f93d6fe4b75b2d3607d04195b05">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240407to20240407"
      id="Fact_59516e5b03ba4320b9d28b9534ddf9ba">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240407to20240407"
      id="Fact_b67a1d74d06949c59723fe2a82eccd9d">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240407to20240407"
      id="Fact_11955e53681d4d68bec9832dab95a509">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240407to20240407"
      id="Fact_9996822d01e54e9d9b8745dc4651be5c">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240407to20240407"
      id="Fact_a840f08092274add96f0ee9fb869a031">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240407to20240407"
      id="Fact_eda278a0d00c40568d38faad5b4a7f30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240407to20240407"
      id="Fact_15d5501369fa4e46885a9a473f60bfc3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240407to20240407"
      id="Fact_0d1afa95d59f4cc28c5aea0dde5860d0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240407to20240407"
      id="Fact_8519f9bc17f3430d80285ed280906074">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240407to20240407"
      id="Fact_60367cb75a0f48b9b94187523a89d59d">&#x201c;IONS&#x201d;</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240407to20240407"
      id="Fact_119de963ad254a7b97d3969bedc8e90c">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
